Ken Hsu
Associate Professor The University of Texas at Austin
Seminars
Wednesday 21st October 2026
Leveraging Covalent Metabolic Targeting to Deliver Next-Generation Precision Therapeutics via Electrophile-Drug Conjugates
10:00 am
- Targeting glycolytic vulnerabilities in cancer through site-specific covalent activation of PFKL to induce metabolic imbalance
- Stabilizing enzyme conformational states via selective covalent modification to disrupt tumor cell metabolism and growth
- Delivering cytotoxic payloads through electrophile-drug conjugates as a novel intracellular alternative to antibody-drug conjugates
